Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA will hold antimicrobial resistance meeting

Executive Summary

On April 28, FDA will hold a public hearing to discuss strategies to limit the development of antimicrobial resistance and the possible effectiveness of economic incentives in promoting development of new antimicrobial agents. Under FDAAA, FDA is required to hold such a public hearing to discuss which life-threatening infectious diseases potentially qualify for grants and contracts under the Orphan Drug Act. In February, the agency was criticized by industry reps at a CAP workshop for not providing clear guidance on what it is looking for in anti-infective drug development, and not offering enough incentives for sponsors to continue R&D in the area
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS049505

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel